Dopamine Is An Indicator But Not An Independent Risk Factor For Reduced Amikacin Clearance In Elbw Infants

Introduction: Important interindividual variability in amikacin clearance was observed in preterm infants, only in part explain by gestational age (GA), birth weight or co-administration of non-selective cyclo-oxgenase (COX) inhibitor (1). We therefore evaluated whether dopamine had an additional effect on amikacin clearance. Methods: Clinical characteristics (GA, weight, COX inhibitor, dopamine, prenatal betamethasone) and amikacin pharmacokinetics were retrospectively collected in a cohort of preterm infants [